As of 30 Sep 2025, 150 institutional investors reported holding 4,719,905 shares of ISHARES TR - U.S. PHARMA ETF (IHE).
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 11,920 | $1,002,191 | +$55,626 | $84.72 | 4 |
| 2025 Q3 | 4,719,905 | $342,444,031 | -$13,869,438 | $72.56 | 150 |
| 2025 Q2 | 4,968,369 | $325,628,195 | -$8,276,832 | $65.54 | 140 |
| 2025 Q1 | 4,897,901 | $345,371,935 | -$38,715,193 | $70.56 | 151 |
| 2024 Q4 | 5,455,870 | $358,605,853 | +$8,069,374 | $65.72 | 155 |
| 2024 Q3 | 5,287,897 | $373,305,187 | -$36,525,906 | $70.61 | 143 |
| 2024 Q2 | 5,821,186 | $386,186,234 | +$20,443,628 | $66.32 | 141 |
| 2024 Q1 | 5,574,758 | $377,592,694 | +$213,233,143 | $67.90 | 138 |
| 2023 Q4 | 1,893,544 | $351,167,088 | +$240,877,855 | $185.40 | 132 |
| 2023 Q3 | 649,931 | $115,057,100 | -$5,412,515 | $176.98 | 124 |
| 2023 Q2 | 675,400 | $121,103,434 | -$9,710,803 | $179.11 | 116 |
| 2023 Q1 | 729,788 | $128,295,664 | -$9,783,894 | $175.28 | 124 |
| 2022 Q4 | 746,550 | $138,876,719 | +$8,758,995 | $186.13 | 126 |
| 2022 Q3 | 691,897 | $117,318,733 | -$7,558,289 | $169.54 | 108 |
| 2022 Q2 | 746,690 | $143,234,000 | +$33,977,360 | $191.65 | 119 |
| 2022 Q1 | 562,474 | $109,355,839 | +$8,370,033 | $194.24 | 116 |
| 2021 Q4 | 520,688 | $104,062,861 | -$3,381,738 | $199.66 | 106 |
| 2021 Q3 | 535,391 | $98,105,652 | +$981,064 | $183.13 | 107 |
| 2021 Q2 | 528,900 | $98,242,898 | +$6,457,088 | $185.74 | 98 |
| 2021 Q1 | 494,172 | $87,783,779 | -$2,263,005 | $177.66 | 99 |
| 2020 Q4 | 506,263 | $90,864,669 | +$3,773,491 | $179.44 | 96 |
| 2020 Q3 | 485,703 | $79,461,411 | -$9,036,327 | $163.53 | 91 |
| 2020 Q2 | 543,697 | $83,671,119 | +$14,088,589 | $153.87 | 88 |
| 2020 Q1 | 451,167 | $60,728,977 | -$20,537,996 | $134.58 | 91 |
| 2019 Q4 | 598,618 | $95,848,471 | -$71,199,280 | $160.11 | 90 |
| 2019 Q3 | 1,049,383 | $146,829,601 | +$43,818,388 | $139.85 | 81 |
| 2019 Q2 | 732,338 | $110,460,525 | +$8,530,469 | $150.79 | 83 |
| 2019 Q1 | 675,083 | $103,940,428 | -$234,018 | $153.97 | 89 |
| 2018 Q4 | 684,374 | $96,343,411 | -$28,861,755 | $140.76 | 92 |
| 2018 Q3 | 877,632 | $147,307,850 | -$909,430 | $167.84 | 95 |
| 2018 Q2 | 876,013 | $132,605,951 | -$9,897,727 | $151.35 | 90 |
| 2018 Q1 | 943,594 | $139,178,080 | -$137,964,573 | $147.54 | 99 |
| 2017 Q4 | 1,847,113 | $285,150,847 | -$31,401,828 | $154.38 | 106 |
| 2017 Q3 | 2,025,449 | $316,744,114 | -$32,562,827 | $156.36 | 99 |
| 2017 Q2 | 2,239,435 | $347,446,485 | -$14,535,839 | $155.13 | 92 |
| 2017 Q1 | 2,302,977 | $347,593,226 | +$60,500,681 | $150.94 | 95 |
| 2016 Q4 | 1,953,627 | $276,365,000 | +$114,944,238 | $141.42 | 92 |
| 2016 Q3 | 1,080,051 | $160,536,000 | -$44,259,881 | $149.44 | 84 |
| 2016 Q2 | 1,360,676 | $196,592,354 | -$20,528,854 | $144.40 | 88 |
| 2016 Q1 | 1,493,303 | $204,750,027 | -$99,286,057 | $136.98 | 90 |
| 2015 Q4 | 1,915,142 | $309,313,814 | -$760,352 | $161.69 | 102 |
| 2015 Q3 | 2,164,584 | $321,148,738 | -$24,117,852 | $148.02 | 102 |
| 2015 Q2 | 2,309,662 | $403,905,318 | -$49,635,232 | $174.82 | 118 |
| 2015 Q1 | 2,536,179 | $437,086,452 | +$86,720,565 | $172.42 | 107 |
| 2014 Q4 | 2,053,922 | $310,975,960 | +$27,141,839 | $151.40 | 101 |
| 2014 Q3 | 1,843,426 | $258,684,490 | -$10,400,820 | $140.35 | 85 |
| 2014 Q2 | 1,917,703 | $259,123,112 | -$2,844,651 | $135.11 | 86 |
| 2014 Q1 | 1,947,975 | $246,644,151 | +$26,495,460 | $126.69 | 85 |